MedTrace Logo

Optimizing Treatments for Heart Failure During Hospitalization

NCT05910437 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2026-02-13

No results posted yet for this study

Summary

Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year.

Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2).

Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality.

The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.

Conditions

  • Decompensated Heart Failure

Interventions

OTHER

Hospitalized patient for decompensated heart failure

Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Nicolas GIRERD, MD-PhD · CHRU de NANCY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-08
Primary Completion
2023-11-29
Completion
2023-11-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05910437 on ClinicalTrials.gov